Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbomer is a high-molecular-weight cross-linked polymer of acrylic acid. In pharmaceutical applications, particularly ophthalmology, it serves as a synthetic tear substitute to manage dry eye syndrome (keratoconjunctivitis sicca). Its therapeutic efficacy stems from its mucoadhesive properties, which allow it to bind to the mucin layer of the ocular surface, and its high viscosity, which ensures a prolonged residence time compared to aqueous drops. By forming a protective and lubricating film, carbomer stabilizes the tear film, reduces tear evaporation, and alleviates symptoms of ocular irritation and dryness. It is commonly formulated as a sterile ophthalmic gel and is also widely used as an excipient (thickening agent) in various topical creams and lotions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbomer.